Eva Renee  Barnett net worth and biography

Eva Barnett Biography and Net Worth

CFO of Immunovant

With two decades of experience in healthcare, Renee is a passionate and effective leader, who thrives in fast-paced growth organizations. Renee began her career at Eli Lilly where her roles included CFO of Lilly Austria and Switzerland, global lead for Financial Planning and Analysis, and financial lead of a partnership with Amylin Pharmaceuticals. Prior to joining Immunovant, she served in a variety of executive leadership functions, including Finance, Human Resources, Data & Analytics, Call Center Operations, and Technology Transformation at AbleTo, Inc., a leading technology-enabled behavioral health provider. Renee holds an M.B.A. from Harvard Business School and a B.A. in Physics from DePauw University.

What is Eva Renee Barnett's net worth?

The estimated net worth of Eva Renee Barnett is at least $10.14 million as of April 17th, 2024. Ms. Barnett owns 359,456 shares of Immunovant stock worth more than $10,143,848 as of April 21st. This net worth estimate does not reflect any other assets that Ms. Barnett may own. Additionally, Ms. Barnett receives a salary of $871,070.00 as CFO at Immunovant. Learn More about Eva Renee Barnett's net worth.

How old is Eva Renee Barnett?

Ms. Barnett is currently 44 years old. There are 6 older executives and no younger executives at Immunovant. The oldest executive at Immunovant is Dr. William L. Macias M.D., Ph.D., Chief Medical Officer, who is 66 years old. Learn More on Eva Renee Barnett's age.

What is Eva Renee Barnett's salary?

As the CFO of Immunovant, Inc., Ms. Barnett earns $871,070.00 per year. The highest earning executive at Immunovant is Dr. Peter Salzmann M.B.A., M.D., CEO & Director, who commands a salary of $1,020,000.00 per year. Learn More on Eva Renee Barnett's salary.

How do I contact Eva Renee Barnett?

The corporate mailing address for Ms. Barnett and other Immunovant executives is 320 WEST 37TH STREET, NEW YORK NY, 10018. Immunovant can also be reached via phone at 917-580-3099 and via email at [email protected]. Learn More on Eva Renee Barnett's contact information.

Has Eva Renee Barnett been buying or selling shares of Immunovant?

In the last ninety days, Eva Renee Barnett has sold $471,095.20 in shares of Immunovant stock. Most recently, Eva Renee Barnett sold 12,253 shares of the business's stock in a transaction on Wednesday, April 17th. The shares were sold at an average price of $29.06, for a transaction totalling $356,072.18. Following the completion of the sale, the chief financial officer now directly owns 359,456 shares of the company's stock, valued at $10,445,791.36. Learn More on Eva Renee Barnett's trading history.

Who are Immunovant's active insiders?

Immunovant's insider roster includes Peter . (), Eva Barnett (CFO), Julia Butchko (Insider), Douglas Hughes (Director), Mark Levine (Chief Legal Officer and Corporate Secretary), William Macias (Insider), George Migausky (Director), Atul Pande (Director), Peter Salzmann (CEO), and Frank Torti (Director). Learn More on Immunovant's active insiders.

Are insiders buying or selling shares of Immunovant?

During the last twelve months, Immunovant insiders bought shares 1 times. They purchased a total of 1,526,316 shares worth more than $58,000,008.00. During the last twelve months, insiders at the sold shares 32 times. They sold a total of 422,975 shares worth more than $10,417,957.68. The most recent insider tranaction occured on April, 17th when CFO Eva Renee Barnett sold 12,253 shares worth more than $356,072.18. Insiders at Immunovant own 4.8% of the company. Learn More about insider trades at Immunovant.

Information on this page was last updated on 4/17/2024.

Eva Renee Barnett Insider Trading History at Immunovant

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/17/2024Sell12,253$29.06$356,072.18359,456View SEC Filing Icon  
4/9/2024Sell3,689$31.18$115,023.02371,709View SEC Filing Icon  
2/22/2024Sell2,930$36.15$105,919.50320,420View SEC Filing Icon  
1/11/2024Sell3,515$41.83$147,032.45323,350View SEC Filing Icon  
11/22/2023Sell4,055$32.78$132,922.90326,865View SEC Filing Icon  
10/10/2023Sell4,557$36.92$168,244.44330,920View SEC Filing Icon  
8/24/2023Sell14,386$20.30$292,035.80335,477View SEC Filing Icon  
7/19/2023Sell2,725$24.94$67,961.50349,863View SEC Filing Icon  
4/18/2023Sell3,423$15.27$52,269.21352,588View SEC Filing Icon  
1/11/2023Sell4,510$16.75$75,542.50268,347View SEC Filing Icon  
10/11/2022Sell12,500$9.44$118,000.00272,857View SEC Filing Icon  
See Full Table

Eva Renee Barnett Buying and Selling Activity at Immunovant

This chart shows Eva Renee Barnett's buying and selling at Immunovant by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Immunovant Company Overview

Immunovant logo
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Read More

Today's Range

Now: $28.22
Low: $27.33
High: $28.64

50 Day Range

MA: $33.00
Low: $28.22
High: $38.36

2 Week Range

Now: $28.22
Low: $15.08
High: $45.58


1,079,132 shs

Average Volume

1,018,913 shs

Market Capitalization

$4.10 billion

P/E Ratio


Dividend Yield